{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Ionis Pharmaceuticals, Inc."},"Symbol":{"label":"Symbol","value":"IONS"},"Address":{"label":"Address","value":"2855 GAZELLE COURT, CARLSBAD, California, 92010, United States"},"Phone":{"label":"Phone","value":"+1 760 931-9200"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019)."},"CompanyUrl":{"label":"Company Url","value":"https://www.ionispharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Brett P. Monia","title":"Chief Executive Officer & Director"},{"name":"C. Frank Bennett","title":"Chief Scientific Officer & Executive VP"},{"name":"Eugene Schneider","title":"Chief Clinical Development Officer & Executive VP"},{"name":"Jessica J. Cornelius","title":"Senior Vice President-Information Technology"},{"name":"Joel Ekstorm","title":"Vice President-Information Technology"},{"name":"Sanjay Bhanot","title":"Chief Medical Officer & SVP"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}